Search results
Showing 61 to 75 of 146 results for pneumonia
Cryotherapy for malignant endobronchial obstruction (IPG142)
Evidence-based recommendations on cryotherapy for malignant endobronchial obstruction. This involves using cold temperatures to destroy the cancer tissue that’s causing a blockage.
View recommendations for IPG142Show all sections
Sections for IPG142
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections....
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders
Evidence-based recommendations on stent insertion for bleeding oesophageal varices. This involves temporarily inserting a tube-shaped mesh covered in plastic (called a stent) into the oesophagus.
View recommendations for IPG392Show all sections
Sections for IPG392
Evidence-based recommendations on the Foker technique for long-gap oesophageal atresia. This involves pulling slightly on the broken ends of the oesophagus to encourage them to grow towards each other so they can be stitched together to form a complete oesophagus.
View recommendations for IPG153Show all sections
Sections for IPG153
Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults (IPG634)
Evidence-based recommendations on transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults. This involves electrically stimulating nerves in the throat or neck, while the person swallows. The aim is to strengthen the muscles involved in swallowing.
View recommendations for IPG634Show all sections
Insertion of endobronchial valves for persistent air leaks (IPG448)
Evidence-based recommendations on insertion of endobronchial valves for treatment of persistent air leaks. This involves inserting valves into the airways to reduce or stop air leaks so the rest of the lung can function normally.
View recommendations for IPG448Show all sections
Sections for IPG448
This quality standard covers managing intravenous (IV) fluid therapy safely and effectively for adults in hospital. It describes high-quality care in priority areas for improvement.
View quality statements for QS66Show all sections
Sections for QS66
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
Comparator, Outcome) P: patients 18 years and under who have COVID-19 pneumonia I: treatment-dose LMWH C: standard prophylaxis with LMWH...
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
Temperature control to improve neurological outcomes after cardiac arrest (IPG782)
Evidence-based recommendations on temperature control to improve neurological outcomes after cardiac arrest. This involves controlling a person’s body temperature while they are still unconscious after their heart has been restarted. Either their body is kept at a normal temperature of between 36.5°C and 37.5°C to prevent fever, or it is cooled to between 32.0°C and 36.0°C (therapeutic hypothermia).
View recommendations for IPG782Show all sections
16 years and over who have been discharged after treatment for COVID-19 pneumonia I: extended (2 to 6 weeks) pharmacological VTE...